Loading stock data…
Precigen, Inc. (PGEN)
$6.87-0.23 (-3.24%)
Market ClosedLast close Sep 8
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Precigen, Inc. in the Healthcare sector is trading at $6.87 with a market capitalization of $2.5B. Wall Street consensus targets $14.50 (2 analysts), implying a +111.1% move over the next 12 months. The stock is currently near its 52-week high of $7.72, remaining 47.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +111.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $54.98M↑ | $23.25M↑ | $4.57M↑ | $2.92M↑ | $856,000 |
| Gross Profit | $52.17M↑ | $20.69M↑ | $2.97M↑ | $1.89M↑ | -$236,000 |
| Operating Income | $22.64M↑ | -$5.99M↑ | -$21.67M↑ | -$34.48M↓ | -$27.86M |
| Net Income | $20.07M↑ | -$7.93M↑ | -$23.50M↑ | -$146.34M↓ | -$26.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-361.91%
Volume
Today's trading volume
2.76M
Recent News
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.